Aviado · Research
Longevity Daily
Friday, October 23, 2026
Listen
Today's Brief
David Sinclair's gene therapy for glaucoma—ER-100—is delivering what once seemed impossible: patients reporting restored vision after cellular reprogramming of retinal cells, making it today's must-read. New mechanistic research explains why APOEε4 carriers face accelerated cognitive decline via myelin destruction, while our Aviado analysis unpacks exactly how PQQ grows new mitochondria in your brain. On the supplement front, a popular product draws a serious heart failure warning, vitamin K2 earns two-year RCT support for slowing arterial calcification, and HHS rolls out an ambitious national Alzheimer's prevention blueprint.
10 stories4 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
David Sinclair's Gene Therapy Is Restoring Vision in Glaucoma Patients—a First for Cellular Age Reversal
A gene therapy called ER-100, developed from Harvard's David Sinclair's lab and commercialized through his startup, is producing striking early human results: glaucoma patients report being able to see again after their retinal ganglion cells were partially reprogrammed using three of the four Yamanaka factors—a safety-conscious approach that resets cellular age markers without triggering uncontrolled division. This is significant well beyond ophthalmology: if biological age can be reliably reversed in one tissue, the same principle could apply to heart, kidney, and brain. Results are early-stage and require larger trial validation, but ER-100 may represent the first credible demonstration of functional tissue rejuvenation in living humans—and the story is being told in plain English with real patient voices.
Read more →Why APOEε4 Accelerates Brain Aging: The Myelin-Destruction Mechanism Scientists Just Mapped
Researchers have found that the APOEε4 Alzheimer's risk variant damages the brain through a second pathway beyond neuroinflammation—it disrupts oligodendrocytes, the cells that maintain myelin, the fatty insulation enabling fast communication between neurons. Because myelin naturally deteriorates with age, APOEε4 carriers effectively get a head start on this damage via the same lipid-metabolism dysfunction already linked to microglial inflammation. For the roughly one-in-four adults carrying APOEε4, this finding highlights new protective targets—including omega-3 fatty acids and other lipid-supporting strategies—that may help preserve myelin integrity alongside conventional amyloid-focused approaches.
Read more →How PQQ Activates PGC-1α to Grow New Mitochondria in Your Brain
PQQ (pyrroloquinoline quinone) triggers mitochondrial biogenesis—the creation of new mitochondria—by activating PGC-1α, a master regulatory protein that declines with age, and human studies confirm measurable improvements in memory, attention, and executive function within 6–12 weeks at 10–20 mg daily. Older adults show particular gains in working memory and verbal recall, alongside reduced inflammatory markers including IL-6 and C-reactive protein, suggesting broader anti-aging effects beyond brain energy. Aviado's full analysis covers the mechanism in plain language, the dihydrogen vs. disodium salt distinction, and the practical tracking approach that tells you whether it's actually working.
Read the full Aviado analysis →Supplements & Compounds
Vitamin K2 Supplement MenaQ7® Slows Arterial Calcification Over Two Years in RCT
The VitaK-CAC trial—a 2-year randomized controlled study of daily MK-7 supplementation (as MenaQ7®) in adults with symptomatic coronary artery disease—found measurable slowing of coronary artery calcification compared to placebo, a meaningful result because arterial calcification is a direct, quantifiable marker of vascular aging. Vitamin K2 works by activating matrix Gla-protein (MGP), which sequesters calcium and prevents it from depositing in arterial walls, and this trial provides some of the most rigorous human evidence yet that K2 delivers on that mechanism in practice. For supplement users already stacking K2 alongside vitamin D and magnesium, this 2-year dataset provides strong support for continuing that protocol.
Read more →Elysium's NAD+ Supplement Shifts Estrogen Ratios and Eases Menopause Symptoms in Pilot Trial
An open-label pilot trial of Elysium's Basis—a combination of nicotinamide riboside (NR) and pterostilbene—found a statistically significant improvement in the estradiol-to-estrone (E2/E1) ratio in menopausal women, alongside improvements in common symptoms including hot flashes, fatigue, and sleep disruption. The E2/E1 ratio matters because estradiol is the more biologically active and protective estrogen form; a favorable shift suggests NAD+ supplementation may support hormonal health beyond its established role in cellular energy metabolism. Results are preliminary—open-label with no placebo arm—but they open an intriguing new research direction for NAD+ precursors in women's longevity.
Read more →Topical Urolithin A Clears Damaged Mitochondria to Rejuvenate Aged Skin
New research explores applying urolithin A directly to skin as a strategy for reversing mitochondrial decline in aged tissue—the compound works by enhancing mitophagy, the cellular housekeeping process that removes damaged mitochondria and makes way for healthier, more efficient replacements. This mechanism mirrors how exercise, caloric restriction, and NAD+ precursors improve cellular energy, suggesting topical urolithin A may work synergistically with oral supplementation rather than duplicate it. The research is preclinical, but the topical route is genuinely novel and may achieve higher local concentrations in skin than oral dosing can deliver.
Read more →One of America's Most Popular Supplements Has an Unexpected Link to Heart Failure
New research flagged by ScienceAlert suggests that one of the best-selling supplements in the US may carry an unintended cardiovascular risk, with data pointing to a concerning association with heart failure—particularly notable because the product is widely taken under the assumption of broad safety. The finding is preliminary but significant enough to warrant attention from anyone taking this supplement without a specific clinical indication or physician oversight. Click through to find out which supplement is under scrutiny and what the current evidence suggests about continuing use.
Read more →Research & Papers
Caloric Restriction and NAD+ May Work Through Brain Cell Cilia—Not Just Metabolism
A provocative new paper proposes that many of the longevity benefits attributed to caloric restriction and elevated NAD+ may actually operate through their effects on neuronal cilia—tiny sensory structures on brain cells that detect metabolic signals and coordinate whole-body physiological responses. If the hypothesis holds, it could explain why NAD+ supplementation produces such variable results across individuals: the bottleneck may not be systemic NAD+ levels, but how well individual neurons transduce those signals at the cilia level. The finding is early and theoretical, but it has real implications for how researchers should design the next generation of caloric restriction mimetics and NAD+ therapies.
Read more →Your Biological Age Test May Be Unreliable for Evaluating Novel Longevity Protocols
Aging clocks—whether methylation-based, protein-based, or otherwise—are trained on conventional aging data, which means they fundamentally cannot assess whether a genuinely new therapy is improving or harming your biology. A novel intervention might produce real, measurable health benefits while appearing unchanged or even 'worse' on a clock that was never calibrated for that type of biological change. Before spending hundreds of dollars on at-home biological age tests to track a new supplement or protocol, this Fight Aging! analysis is required reading on what those numbers can and cannot actually tell you.
Read more →Industry & Policy
HHS Launches Bold National Alzheimer's Plan Focused on Lifelong Prevention—Not Just Treatment
The U.S. Department of Health and Human Services has released a sweeping update to the national Alzheimer's and dementia strategy, with greater emphasis on reducing risk across the entire lifespan rather than managing disease after it becomes symptomatic. The plan formally incorporates related dementias beyond Alzheimer's, reflecting growing recognition of shared pathologies across neurodegenerative diagnoses, and focuses on translating research discoveries into accessible prevention and care delivery. For the longevity-focused community, the policy shift is significant: it reflects growing institutional consensus that dementia prevention must begin decades before symptoms appear—and that it is achievable.
Read more →